Introduction
Methods
Search strategy, inclusion and exclusion criteria
Screening, data extraction and quality assessment
Statistical analysis
Results
Worldwide rates of carditis
Author (last name) | Year published | Study location (country) | Study design |
---|---|---|---|
Bozkurt | 2021 | United States (VAERS) | Vaccine reporting system |
Chouchana | 2022 | Global (Vigibase) | Case–non-case study |
Chua* | 2021 | Hong Kong, China | Cohort study |
Foltran | 2021 | Global (Vigibase) | Vaccine reporting system |
Hause | 2021 | United States | VAER report |
Krug* | 2022 | United States | Vaccine reporting system |
Li | 2022 | China | Case–control study |
Truong* | 2021 | United States (VAERS) | Vaccine reporting system |
Li * | 2021 | Hong Kong, China | Cohort study |
Buchan* | 2021 | Canada | Cohort study |
Mevorache* | 2021 | Israel | Cohort study |
Nygaard | 2022 | Denmark | Cohort study and case series |
Comparison | Pooled rate ratio (95% confidence interval) |
---|---|
Male vs female | 5.04 (1.40, 18.19) |
Dose 2 vs dose 1 | 5.60 (1.97, 15.89) |
Vaccination | Background | COVID-19 infection | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Study | Location | Age group | Rate per million | Rate ratio | Age group | Rate per million | Rate ratio | Age group | Rate per million | Rate ratio |
Overall | ||||||||||
Buchan 2021 [55] | Ontario, Canada | 12–17 | 38.17 (28.76, 38.17) | 1 | 16–19 | 2.570 (2.071, 3.145) [56] | 0.0673 (0.0193, 0.2351) | – | – | – |
Chua 2021[42] | Hong Kong, China | 12–17 | 57.30 (39.91, 79.69) | 1 | 12–17 | 2.3 (0.275, 16.08) [42] | 0.0401 (0.0021, 0.7359) | – | – | – |
Oster 2022b[14] | United States | 12–17 | 53.89 (49.27, 58.95) | 1 | 15–18a | 0.2877 (0.28, 0.2953) [57] | 0.0053 (0.0041, 0.0070) | 12–17 | 44.34 (22.56, 93.66) [58] | 0.8228 (0.2770, 2.444) |
Mevorach 2021b [59] | Israel | 16–19 | 10.25 (7.176, 14.19) | 1 | – | – | – | 16–19 | 14.15 (3.855, 38.23) [59] | 1.381 (0.4915, 3.880) |
Dose 1 | ||||||||||
Buchan 2021 [55] | Ontario, Canada | 12–17 | 24.70 (14.87, 38.57) | 1 | 16–19 | 2.570 (2.071, 3.145) [56] | 0.1041 (0.0283, 0.3828) | – | – | – |
Chua 2021[42] | Hong Kong, China | 12–17 | 16.85 (6.183, 36.76) | 1 | 12–17 | 2.3 (0.275, 16.08) [42] | 0.1365 (0.0068, 2.737) | – | – | – |
Oster 2022b[14] | United States | 12–17 | 5.85 (4.41, 7.76) | 1 | 15–18a | 0.2877 (0.28, 0.2953) [57] | 0.0492 (0.0219, 0.1107) | 12–17 | 44.34 (22.56, 93.66) [58] | 7.579 (2.003, 28.68) |
Dose 2 | ||||||||||
Buchan 2021 [55] | Ontario, Canada | 12–17 | 53.60 (37.54, 74.20) | 1 | 16–19 | 2.570 (2.071, 3.145) [56] | 0.0479 (0.0135, 0.1700) | – | – | – |
Chua 2021[42] | Hong Kong, China | 12–17 | 106.1 (71.06, 153.4) | 1 | 12–17 | 2.3 (0.275, 16.08) [42] | 0.0217 (0.0012, 0.3990) | – | – | – |
Oster 2022b[14] | United States | 12–17 | 69.06 (62.83, 75.90) | 1 | 15–18a | 0.2877 (0.28, 0.2953) [57] | 0.0042 (0.0033, 0.0053) | 12–17 | 44.34 (22.56, 93.66) [58] | 0.6421 (0.2177, 1.893) |
Male | ||||||||||
Buchan 2021[55] | Ontario, Canada | 12–17 | 54.74 (39.11, 74.54) | 1 | 16–19 | 2.570 (2.071, 3.145) [56] | 0.0470 (0.0133, 0.1657) | – | – | – |
Chua 2021[42] | Hong Kong, China | 12–17 | 94.18 (63.07, 135.3) | 1 | 12–17 | 2.3 (0.275, 16.08) [42] | (0.0244 (0.0013, 0.4494) | – | – | – |
Oster 2022b[14] | United States | 12–17 | 66.54 (60.57, 73.11) | 1 | 15–18a | 0.2877 (0.28, 0.2953) [57] | 0.0043 (0.0034, 0.0055) | 12–17 | 44.34 (22.56, 93.66) [58] | 0.6663 (0.2257, 1.967) |
Female | ||||||||||
Buchan 2021[55] | Ontario, Canada | 12–17 | 21.12 (11.82, 34.84) | 1 | 16–19 | 2.570 (2.071, 3.145) [56] | 0.1216 (0.0150, 0.2797) | – | – | – |
Chua 2021[42] | Hong Kong, China | 12–17 | 19.81 (7.269, 43.11) | 1 | 12–17 | 2.3 (0.275, 16.08) [42] | 0.1151 (0.0058, 2.328) | – | – | – |
Oster 2022b[14] | United States | 12–17 | 6.71 (4.99, 9.02) | 1 | 15–18a | 0.2877 (0.28, 0.2953) [57] | 0.0429 (0.0201, 0.0915) | 12–17 | 44.34 (22.56, 93.66) [58] | 6.608 (1.803, 24.21) |
Clinical characteristics
Author (last name) | Year published | Study location (Country) | Study design | Total number of myopericarditis |
---|---|---|---|---|
Ambati | 2021 | United States | Case series | 2 |
Azir | 2021 | United States | Case report | 1 |
Buchhorn | 2021 | Germany | Case report | 1 |
Chelala | 2022 | United States | Case series | 5 |
Das | 2021 | United States | Case series | 25 |
Di | 2022 | Italy | Case series | 1 |
Dionne | 2021 | United States | Case series | 15 |
Giray | 2022 | Turkey | Case report | 1 |
Manfredi | 2022 | Italy | Case series | 6 |
Marshall | 2021 | United States | Case series | 7 |
McLean | 2021 | United States | Case study | 1 |
Minocha | 2021 | United States | Case study | 1 |
Poussaint | 2021 | United States | Case report | 1 |
Snapiri | 2021 | Israel | Case series | 7 |
Tano | 2021 | United States | Case series | 8 |
Truong | 2022 | Canada, United States | Case report | 140 |
Türe | 2022 | Turkey | Case report | 1 |
Visclosky | 2021 | United States | Case report | 1 |
Jain | 2021 | United States | Case series | 31 |
Starekova | 2021 | United States | Case series | 2 |
Abu Mouch | 2021 | Israel | Case series | 2 |
Fleming-nouri | 2021 | United States | Case series | 3 |
Park | 2021 | United States | Case series | 2 |
Shaw | 2021 | United States | Case series | 2 |
Patel | 2021 | United States | Case series | 9 |
Schauer | 2021 | United States | Case series | 13 |
Nygaard | 2022 | Denmark | Cohort study and case series | 13 |
Patient characteristics (n = 301) | Mean/number | Standard deivation/% |
---|---|---|
Patient demographics | ||
Age (year) | 15.90 | 1.52 |
Male | 281 | 93.36% |
Clinical diagnosis | ||
Total carditis | 301 | 100.00% |
Total myocarditis | 240 | 79.73% |
Total pericarditis | 5 | 1.66% |
Unclassified | 56 | 18.60% |
Subgroup | ||
Carditis after first dose | 38 | 12.62% |
Carditis after second dose | 263 | 87.38% |
Pericarditis after first dose | 3 | 60.00% |
Pericarditis after second dose | 2 | 40.00% |
Myocarditis after first dose | 30 | 12.50% |
Myocarditis after second dose | 210 | 87.50% |
Proportion of vaccine types | ||
BNT162b2 | 339 | 79.39% |
mRNA-1273 | 85 | 19.91% |
Ad26.COV2.S | 1 | 0.23% |
Unknown | 2 | 0.47% |
Admission | ||
Length of stay (days) | 3.905 | 1.75 |
Intensive care unit | 53 | 20.31 |
Resolution | 298 | 99.00% |
Clinical manifestation | ||
Chest pain | 293 | 97.34% |
Fever | 113 | 37.54% |
Shortness of breath | 64 | 21.26% |
Myalgia | 51 | 16.94% |
Headache | 47 | 15.61% |
Nausea and vomiting | 31 | 10.30% |
Palpitations | 8 | 2.66% |
Laboratory results | ||
Troponin (ng/mL) | 924.32 | 2017.01 |
Median (Q1 to Q3) | 9.62 (5.40–828.09) | – |
Min; max | 0.03; 7368.45 | – |
C-reactive protein level (mg/mL) | 25.89 | 44.31 |
Median (Q1–Q3) | 7.58 (4.06–24.70) | |
Min; max | 0.57; 174 | |
Treatment | ||
Treatment received | 261 | 86.71% |
NSAIDs | 226 | 86.59% |
Steroids | 50 | 19.16% |
Intravenous immunoglobulins | 57 | 21.84% |
Angiotensin-converting enzyme (ACE) inhibitors | 2 | 0.77% |
Colchicine | 24 | 9.20% |